During the last session, IGC Pharma Inc (AMEX:IGC)’s traded shares were 0.34 million, with the beta value of the company hitting 1.45. At the end of the trading day, the stock’s price was $0.31, reflecting an intraday gain of 0.56% or $0.01. The 52-week high for the IGC share is $0.91, that puts it down -193.55 from that peak though still a striking 16.13% gain since the share price plummeted to a 52-week low of $0.26. The company’s market capitalization is $24.42M, and the average trade volume was 405.85K shares over the past three months.
IGC Pharma Inc (IGC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. IGC has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.02.
IGC Pharma Inc (AMEX:IGC) trade information
IGC Pharma Inc (IGC) registered a 0.56% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.56% in intraday trading to $0.31, hitting a weekly high. The stock’s 5-day price performance is 5.66%, and it has moved by -3.37% in 30 days. Based on these gigs, the overall price performance for the year is -8.62%.
IGC Pharma Inc (IGC) estimates and forecasts
In the rating firms’ projections, revenue will decrease -7.36% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 305k as predicted by 2 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 326k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 295k and 272k respectively. In this case, analysts expect current quarter sales to grow by 3.39% and then jump by 19.85% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -13.79%. While earnings are projected to return 54.55% in 2025, the next five years will return 18.29% per annum.
IGC Dividends
IGC Pharma Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 0.65 million shares, is of VANGUARD GROUP INC’s that is approximately 1.0965% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.28 million.
Also, the Mutual Funds coming in first place with the largest holdings of IGC Pharma Inc (IGC) shares are Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Extended Market Index Fund owns about 630.22 shares. This amounts to just over 1.59 percent of the company’s overall shares, with a $0.19 million market value. The same data shows that the other fund manager holds slightly less at 381.64, or about 0.96% of the stock, which is worth about $0.12 million.
